ConductScience.org, home

Comparison · NCT01757535-deaths

Oral Azacitidine Plus Best Supportive Care vs Placebo Plus Best Supportive Care: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Oral Azacitidine Plus Best Supportive Care vs Placebo Plus Best Supportive Care: deaths from any cause. Trial comparisons, record NCT01757535-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01757535-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.7230.6630.776wilson
Risk in group 20.7520.6930.803wilson
Risk difference, group 1 minus group 2-0.0294-0.1080.0499newcombe hybrid score
Risk ratio, group 1 over group 20.9610.8631.07log
Odds ratio, group 1 over group 20.8590.571.29log
Number needed to treat, for one fewer death from any cause on Oral Azacitidine Plus Best Supportive Care than on Placebo Plus Best Supportive Care34from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Oral Azacitidine Plus Best Supportive Care
Participants received 300 mg azacitidine tablets once a day (QD) for the first 14 days of each 28-day treatment cycle until discontinuation, which includes the following reasons: disease relapse, withdrawal of consent, adverse events, participant became eligible for allogeneic bone marrow or stem cell transplantation during the treatment period, death, lost to follow-up, or protocol violation or until the end of the study.
172238EG000
Group 2Placebo Plus Best Supportive Care
Participants received identically matching placebo tablets QD for the first 14 days of each 28-day treatment cycle until no longer receiving benefit, withdrawal of consent, disease relapse, adverse events, participant became eligible for allogeneic bone marrow or stem cell transplantation during the treatment period, lost to follow-up, or protocol violation or until the end of the study.
176234EG001

Harm

What it counts
Total, all-cause mortality
Time frame
From day 1 (randomization) up to data cut off date of 06 August 2024; approximately 135.5 months

Source ClinicalTrials.gov

Trial

Title
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission
NCT number
NCT01757535
Phases
PHASE3
Conditions
Leukemia, Myeloid, Acute
Interventions
Oral Azacitidine, Placebo
Lead sponsor
Celgene
Results first posted
2020-11-06

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01757535-deaths